Cosmos Health Lands $4.50 Valuation in Zacks Small-Cap Research Debut

## Zacks Small-Cap Research Initiates Coverage on Cosmos Health with $4.50 Price Target, Citing Diversified Growth and Tech Integration

**New York, NY – January 14, 2026** – Cosmos Health Inc. (NASDAQ: COSM), a global healthcare group with a diversified and vertically integrated model, announced today that Zacks Small-Cap Research has initiated coverage on the company. The independent research firm has set a price target of $4.50 per share, underpinned by a five-year discounted cash flow (DCF) analysis.

The valuation, detailed in a report published on January 13, 2026, by analyst Brad Sorensen, reflects Zacks’ projections for robust revenue expansion and Cosmos Health’s strategic move towards higher-margin offerings. Zacks forecasts a significant uptick in revenue, projecting it to climb from approximately $64.4 million in 2025 to $98.6 million in 2026, and further surpass $130 million by 2027. This growth is anticipated to be fueled by the company’s expanding portfolio of high-margin pharmaceuticals, its established nutraceutical brands, the burgeoning telehealth sector, and its innovative Cloudscreen AI-enabled research and development platform.

Zacks highlighted several key pillars supporting its optimistic outlook for Cosmos Health. These include the company’s strategic expansion into the United States market, notably through the acquisition of ZipDoctor, a U.S.-based direct-to-consumer telehealth platform, and the introduction of its Sky Premium Life nutraceutical brand. Furthermore, the report acknowledges a disclosed $300 million financing facility, which provides financial flexibility, and the company’s strategic allocation to digital assets, including Ethereum purchases.

The research firm also pointed to Cosmos Health’s recent financial performance, citing record-breaking revenue and improved adjusted EBITDA in the third quarter of 2025 as evidence of the company’s operational execution and increasing profitability.

**Key Drivers Identified by Zacks Small-Cap Research:**

* **Projected Revenue Acceleration:** Zacks anticipates revenue growth of over 53% from $64.4 million in 2025 to $98.6 million in 2026, with continued expansion to exceed $130 million by 2027. This growth trajectory is attributed to a focus on higher-margin pharmaceutical products and branded nutraceuticals.
* **Valuation Framework:** The $4.50 per share valuation is derived from a five-year DCF model employing a 20% discount rate. This rate acknowledges the inherent risks associated with small-cap companies while factoring in an assumed terminal growth rate of 2%.
* **Integrated Healthcare Ecosystem:** Zacks emphasized the strength of Cosmos Health’s vertically integrated model, which encompasses pharmaceutical distribution, GMP-certified manufacturing, proprietary nutraceutical brands, and advanced R&D capabilities.
* **U.S. Market Penetration:** The acquisition of ZipDoctor signifies a critical step in Cosmos Health’s U.S. telehealth strategy, while the launch of Sky Premium Life targets the lucrative U.S. nutraceutical market.
* **AI-Powered R&D:** The integration of Cloudscreen, an AI platform focused on drug repurposing, is seen as a significant technological advantage, potentially accelerating R&D timelines and reducing discovery costs. This is particularly relevant for the company’s development programs, including CCX0722 for obesity and weight management, as well as other compounds targeting significant disease areas.
* **Financial Fortitude and Flexibility:** The report notes the company’s robust Q3 2025 performance and the availability of a substantial $300 million financing facility, providing capital for strategic initiatives and potential future acquisitions.
* **Digital Asset Strategy:** Cosmos Health’s allocation to digital assets, specifically Ethereum, presents an opportunity for diversification and potential yield generation, though it also introduces exposure to cryptocurrency market volatility.

In response to the coverage, Greg Siokas, CEO of Cosmos Health, stated, “We are pleased to see Zacks Small-Cap Research initiate coverage of Cosmos Health and recognize the transformation we have been executing across our organization. This coverage underscores the strength of our vertically integrated model, our accelerating revenue growth, and the strategic importance of our investments in AI-driven drug repurposing, proprietary pharmaceutical and nutraceutical brands, and digital health services. As we continue to scale higher-margin products, advance our R&D pipeline, and improve operational efficiency, we believe Cosmos Health is entering an important inflection point with substantial long-term value creation potential for our shareholders.”

Cosmos Health has disclosed that it compensated Zacks Small-Cap Research for the preparation and publication of this research report. The company views this as a means to provide shareholders with broader access to independent analysis, fostering transparency and informed investment decisions.

**About Cosmos Health Inc.**

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group dedicated to improving health outcomes through innovative pharmaceutical and nutraceutical products and services. The company’s portfolio includes proprietary brands such as Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept®, and C-Scrub®. Through its subsidiary Cana Laboratories S.A., Cosmos Health manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices in compliance with EU Good Manufacturing Practices (GMP) and European Medicines Agency (EMA) standards. The company also distributes a wide array of pharmaceuticals and parapharmaceuticals across Europe. Cosmos Health is actively engaged in R&D partnerships focused on major health disorders like obesity, diabetes, and cancer, leveraging artificial intelligence for drug repurposing. Further expanding its reach, the company has entered the telehealth sector with the acquisition of ZipDoctor, Inc. and is strategically expanding its global presence across Europe, Asia, and North America.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Readers are cautioned not to place undue reliance on these statements and are encouraged to review the risk factors detailed in the Company’s SEC filings. Cosmos Health disclaims any obligation to update or revise these forward-looking statements.